AspirinWorks 11-Dehydrothromboxane B2 (11-dhTXB2) with Creatinine Test
This urine test measures 11-dehydrothromboxane B2 (11-dhTXB2), the main breakdown product of platelet-derived thromboxane B2, reported together with urine creatinine.
About this test
Aspirin works by blocking an enzyme in platelets called cyclooxygenase, which lowers thrombosis risk by impairing platelet function. Quest notes that some people do not show this expected response, described as 'aspirin resistant.
This measurement may be used in people with cardiovascular disease before starting aspirin therapy, or in people who do not respond to aspirin's platelet-inhibiting effects.
Test details
| Collection | Quest patient service center |
|---|
Quest resources
Additional details
What this test looks at
The result reports three values from the same urine sample: 11-dhTXB2 itself, the 11-dhTXB2-to-creatinine ratio, and urine creatinine. Quest lists the methodology as a combination of calculation, enzymatic, and immunoassay methods used together to produce these three reported values.
This test isn't part of the Celio Health store at the moment, so it can't be ordered or requested here. The test menu lists everything that can.
Laboratory results should always be interpreted by a licensed clinician who knows your health history. This page is information about a test, not medical advice.
Frequently asked questions
What does this test measure?
It measures 11-dehydrothromboxane B2, the main breakdown product of platelet-derived thromboxane B2, in a urine sample, reported together with urine creatinine.
How is the sample collected?
The test uses a 4 mL random preserved urine sample.
Do I need to prepare for this test?
No preparation instructions are listed for this test, though people follow any instructions their ordering clinician provides.
What is 'aspirin resistance'?
It is the term Quest uses for when a person with cardiovascular disease does not show the platelet-inhibiting response usually expected from aspirin. This test's result relates to that concept.